Tryp Therapeutics recently announced interim results from its Phase II trial with psilocybin in the treatment of binge eating disorder,
Tryp Therapeutics recently announced interim results from its Phase II trial with psilocybin in the treatment of binge eating disorder,
2023 is expected to be a pivotal year for psychedelic-assisted therapy, with multiple compounds entering the final stages of drug
Awakn Life Sciences announced that its Phase III clinical trial with ketamine-assisted therapy for the treatment of alcohol-use disorder would
On Friday, atai Life Sciences shared results from its Phase IIa trial with PCN-101, R-ketamine, for treatment-resistant depression. Disappointingly, the
The Psychedelics Newsletter is the sector’s best-read investment focused newsletter, with over 25,000 subscribers. Featuring in-depth market analysis and interviews
In the final quarter of 2022, Beckley Psytech shared updates on its drug development pipeline and reported the acquisition of
Despite a challenging economic climate in the latter half of 2022, the year was marked by major milestones in psychedelic
UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows
On Tuesday, 29 November, PSYCH released the fourth edition of The Psychedelics as Medicine Report. The report, expanded to include
Veteran affairs receive bipartisan support across North America, with public opinion prompting lawmakers and regulators to support innovations in veteran
Tomorrow, Thursday, 17 November, industry leaders will meet in London for Emerging Innovations in Psychedelic Healthcare, to evaluate milestones in
Psych Capital Plc is pleased to announce the appointment of the Conservative Drug Policy Reform Group (CDPRG) representative, Crispin Blunt